SG11201803962WA - Compounds for medicinal applications - Google Patents

Compounds for medicinal applications

Info

Publication number
SG11201803962WA
SG11201803962WA SG11201803962WA SG11201803962WA SG11201803962WA SG 11201803962W A SG11201803962W A SG 11201803962WA SG 11201803962W A SG11201803962W A SG 11201803962WA SG 11201803962W A SG11201803962W A SG 11201803962WA SG 11201803962W A SG11201803962W A SG 11201803962WA
Authority
SG
Singapore
Prior art keywords
victoria
international
compounds
munro
avenue
Prior art date
Application number
SG11201803962WA
Inventor
Betty Jin
Ee-Ling Seah
Paul Arthur; Jones
Peter James Jenkins
Henry Kenneth Windle
Wen Yang Wu
Original Assignee
Australian Biomedical Co Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015904895A external-priority patent/AU2015904895A0/en
Application filed by Australian Biomedical Co Pty Ltd filed Critical Australian Biomedical Co Pty Ltd
Publication of SG11201803962WA publication Critical patent/SG11201803962WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau IIIIII 111111111111111111 DEEM II III IIIIIIIIIIIIIII DEMI RID IIII (10) International Publication Number WO 2017/083914 Al WIPO I PCT (43) International Publication Date 26 May 2017 (26.05.2017) (74) Agent: DAVIES COLLISON CAVE PTY LTD; Level 15, 1 Nicholson Street, Melbourne, Victoria 3000 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art 21(3)) (51) International Patent Classification: A61K 31/351 (2006.01) CO7K 9/00 (2006.01) C07D 407/12 (2006.01) C07D 407/14 (2006.01) A61P 31/16 (2006.01) (21) International Application Number: PCT/AU2016/051100 (22) International Filing Date: 16 November 2016 (16.11.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2015904895 20 November 2015 (20.11.2015) AU (71) Applicant: AUSTRALIAN BIOMEDICAL CO. PTY LTD [AU/AU]; 34 Munro Avenue, Mount Waverley, Vic- toria 3149 (AU). (72) Inventors: JIN, Betty; 34 Munro Avenue, Mount Waver- ley, Victoria 3149 (AU). SEAH, Ee-Ling; 12 Adam Aven- ue, Wheelers Hill, Victoria 3150 (AU). JONES, Paul Ar- thur; 47 Yongala Street, Balwyn, Victoria 3103 (AU). JENKINS, Peter James; 6 Grandview Grove, East Prahran, Victoria 3181 (AU). WINDLE, Henry Kenneth; 192 Franklin Road, Portsea, Victoria 3944 (AU). WU, Wen Yang; 34 Munro Avenue, Mount Waverley, Victoria 3149 (AU). W O 20 17 /0839 14 Al (54) Title: COMPOUNDS FOR MEDICINAL APPLICATIONS (57) : The present invention provides compounds for use in treating and/or preventing influenza. The compound comprises a first and second domain in which the first domain comprises at least one anchoring group which binds to the surface of influenza viruses and the second domain comprises at least one anionic group. The first and second domains are covalently linked. Also provided are phaiinaceutically acceptable salts, solvates, prodrugs or stereoisomer of the compounds.
SG11201803962WA 2015-11-20 2016-11-16 Compounds for medicinal applications SG11201803962WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015904895A AU2015904895A0 (en) 2015-11-20 Compounds for medicinal applications
PCT/AU2016/051100 WO2017083914A1 (en) 2015-11-20 2016-11-16 Compounds for medicinal applications

Publications (1)

Publication Number Publication Date
SG11201803962WA true SG11201803962WA (en) 2018-06-28

Family

ID=58717109

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803962WA SG11201803962WA (en) 2015-11-20 2016-11-16 Compounds for medicinal applications

Country Status (19)

Country Link
US (1) US11007274B2 (en)
EP (1) EP3377487B1 (en)
JP (1) JP7034913B2 (en)
KR (1) KR20180083402A (en)
CN (1) CN108473483B (en)
AU (1) AU2016356726C1 (en)
BR (1) BR112018010027A2 (en)
CA (1) CA3005774C (en)
EA (1) EA033921B9 (en)
ES (1) ES2911027T3 (en)
IL (1) IL259425B (en)
MX (1) MX2018005999A (en)
MY (1) MY195168A (en)
PH (1) PH12018501076A1 (en)
SG (1) SG11201803962WA (en)
TW (1) TWI742015B (en)
UA (1) UA126654C2 (en)
WO (1) WO2017083914A1 (en)
ZA (1) ZA201803214B (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
BR9714299A (en) 1996-11-14 2000-04-25 Biota Scient Mangent Pty Ltd Macromolecular compound, processes for the detection of influenza virus and treatment of influenza infection, pharmaceutical composition for this treatment and use of compound
AUPP913999A0 (en) * 1999-03-12 1999-04-01 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR001000A0 (en) * 2000-09-08 2000-10-05 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR879501A0 (en) 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
DE102004002132A1 (en) * 2004-01-15 2005-08-11 Man Roland Druckmaschinen Ag Device for producing a coating of printed products of a printing machine
JP5950390B2 (en) * 2012-03-26 2016-07-13 国立大学法人 琉球大学 New mimosine derivatives
US10130714B2 (en) * 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
GB201313201D0 (en) * 2013-07-24 2013-09-04 Univ East Anglia Virus Detection
CN105085455A (en) * 2014-05-13 2015-11-25 中国科学院广州生物医药与健康研究院 Sialic acid analogues or pharmaceutically acceptable salts and application thereof

Also Published As

Publication number Publication date
AU2016356726C1 (en) 2021-12-09
UA126654C2 (en) 2023-01-11
EA033921B1 (en) 2019-12-10
CA3005774C (en) 2024-01-09
IL259425B (en) 2021-10-31
CN108473483B (en) 2022-08-30
ZA201803214B (en) 2019-07-31
EA201891072A1 (en) 2018-11-30
AU2016356726B2 (en) 2021-02-25
NZ742593A (en) 2023-08-25
US20180264128A1 (en) 2018-09-20
EP3377487A4 (en) 2019-07-17
AU2016356726A1 (en) 2018-06-07
MY195168A (en) 2023-01-11
EP3377487B1 (en) 2022-01-12
EP3377487A1 (en) 2018-09-26
JP2019502662A (en) 2019-01-31
CA3005774A1 (en) 2017-05-26
CN108473483A (en) 2018-08-31
KR20180083402A (en) 2018-07-20
TWI742015B (en) 2021-10-11
PH12018501076A1 (en) 2019-01-28
WO2017083914A1 (en) 2017-05-26
IL259425A (en) 2018-07-31
MX2018005999A (en) 2018-11-22
TW201726641A (en) 2017-08-01
US11007274B2 (en) 2021-05-18
JP7034913B2 (en) 2022-03-14
EA033921B9 (en) 2020-01-22
BR112018010027A2 (en) 2018-11-21
ES2911027T3 (en) 2022-05-17

Similar Documents

Publication Publication Date Title
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201907034PA (en) Methods of treating influenza
SG11201810485SA (en) Substituted carbonucleoside derivatives useful as anticancer agents
SG11201808220VA (en) Allosteric modulators of nicotinic acetylcholine receptors
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201810168UA (en) Curtain wall
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201806480UA (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
SG11201808686VA (en) Synthesis of indazoles
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201805649UA (en) Therapeutic anti-cd9 antibody
SG11201900689RA (en) Compounds and compositions and uses thereof
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201908114UA (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
SG11201805387RA (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
SG11201811686UA (en) 18f-labeled triazole containing psma inhibitors